Published in
Elsevier, European Journal of Cancer, (68), p. 1-10
DOI: 10.1016/j.ejca.2016.08.026
Links
- ORCID
- ORCID
- ORCID
- Elsevier
- [hdl.handle.net]
- [pure.qub.ac.uk] | PDF
- [pure.qub.ac.uk] | PDF
- [eprints.gla.ac.uk] | PDF
- [www.research.manchester.ac.uk] | PDF
Tools
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Journal article published in 2016 by
David Jamieson 
,
Melanie J. Griffin,
Julieann Sludden,
Yvette Drew,
Nicola Cresti,
Karen Swales,
Mark Merriman,
Rodger Allen,
Paul Bevan,
Markus Buerkle,
Carola Mala,
Vicky Coyle,
Lisa Rodgers,
Emma J. Dean ,
Alastair Greystoke
and other authors.
,
Melanie J. Griffin,
Julieann Sludden,
Yvette Drew,
Nicola Cresti,
Karen Swales,
Mark Merriman,
Rodger Allen,
Paul Bevan,
Markus Buerkle,
Carola Mala,
Vicky Coyle,
Lisa Rodgers,
Emma J. Dean ,
Alastair Greystoke
and other authors.
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, WX-554, and to determine the optimal biological dose for subsequent trials.